Proton Partners International promises “job opportunities that will play a key role in boosting the local economy” as its Liverpool centre progresses.
The development will be one of four currently being carried out by Proton Partners International, making the company the world’s largest developer of proton beam therapy centres.
Set to be known as The Rutherford Cancer Centre North West, the oncology centre will offer chemotherapy, traditional radiotherapy and imaging as well as proton beam therapy to patients.
Following the approval of the project, it is expected that conventional treatments will be available in 2018 and proton beam therapy in 2019.
Mike Moran, chief executive officer of Proton Partners International, says: “This marks the next step in our mission to make the best cancer technology accessible to patients across the UK and I’m proud that our next centre will be in my home town of Liverpool.
“By building centres across the country we hope to transform the level of cancer treatment available to patients and therefore receiving planning permission is a key milestone for us. Not only will our centre bring an innovative industry to Liverpool, but it will also bring skilled job opportunities that will play a key role in boosting the local economy.”
Proton Partners International is building three other UK cancer centres in Newport, Northumberland and Reading, and further sites are said to be under consideration.
Each of the four facilities is expected to be able to treat up to 500 patients a year and the services will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.
Proton Partners International is also building a genomics research centre at the Life Sciences Accelerator building in Liverpool which will be the first part of a health campus set to surround the £335m new Royal Liverpool Hospital.
The genomics programme will support Proton Partners International’s broader research work with the University of Liverpool’s physics department.